Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.75 +0.02 (+0.23%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Cash from Financing Activities (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Cash from Financing Activities came in at $130600.0 in Q4 2025, up 133.2% on a QoQ basis from $56003.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Cash from Financing Activities (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Cash from Financing Activities data on file, last reported at $130600.0 in Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A year-over-year to $130600.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (changed N/A YoY) and the FY2025 annual result came in at $231.7 million, up 133351.97% from the prior year.
  • Cash from Financing Activities advanced to $130600.0 in Q4 2025, from $56003.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $231.4 million in Q1 2025 to a low of $56003.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -
8 Gores Holdings X 385.06 Mn 384.87 Mn - -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 130,600.00
Dec 31, 2025 130,600.00
Sep 30, 2025 56,003.00
Sep 30, 2025 56,003.00
Jun 30, 2025 106,554.00
Jun 30, 2025 106,554.00
Mar 31, 2025 231.40 Mn
Mar 31, 2025 231.40 Mn